Coagulation Factor Ix Recombinant Human

CHEMBL2109205 Phase 4 ได้รับการอนุมัติ Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A laboratory-produced version of human clotting factor IX used to treat and prevent bleeding in patients with hemophilia B. It replaces or supplements the missing clotting protein to allow normal blood coagulation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A laboratory-produced version of human clotting factor IX used to treat and prevent bleeding in patients with hemophilia B. It replaces or supplements the missing clotting protein to allow normal blood coagulation.

Yes, Coagulation Factor Ix Recombinant Human is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2109205. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

กำลังมองหาข้อมูลที่เข้าใจง่ายสำหรับผู้ป่วยอยู่ใช่ไหม?

Coagulation Factor Ix Recombinant Human บน PillFYI

ข้อมูลด่วน

คำพ้องความหมาย: 2

ลิงก์ภายนอก

ChEMBL CHEMBL2109205

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.